Product Description
Pentosan polysulfate (pentosan polysulfate sodium; ELMIRON), a heparin-like, sulfated polysaccharide, is used to manage bladder pain and discomfort in adults with interstitial cystitis (IC). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16706553/)
Mechanisms of Action: NNRT Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: Subcutaneous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Croatia | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Korea | Latvia | Lithuania | Netherlands | Norway | Peru | Poland | Portugal | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Paradigm
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Osteoarthritis, Knee
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PARA_OA_002 | P3 |
Active, not recruiting |
Osteoarthritis, Knee |
2024-10-15 |
19% |